Back to top

Image: Bigstock

Bristol-Myers Squibb (BMY) Catches Eye: Stock Jumps 5%

Read MoreHide Full Article

Bristol-Myers Squibb Company (BMY - Free Report) was a big mover last session, as the company saw its shares rise more than 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $42.77–$46.68 in the past one-month time frame, witnessed a sharp increase yesterday.

The move came after the company reported solid second-quarter 2019 results.

The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Bristol-Myers Squibb currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.

Another stock worth considering in the Large Cap Pharmaceuticals industry is AbbVie Inc. (ABBV - Free Report) which carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Is BMY going up? Or down? Predict to see what others think:Up or Down

Biggest Tech Breakthrough in a Generation

Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.

A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 7 stocks to watch. The report is only available for a limited time.

See 7 breakthrough stocks now>>


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Bristol Myers Squibb Company (BMY) - free report >>

AbbVie Inc. (ABBV) - free report >>

Published in